Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
67.67 (1y: +23%)
Market Cap 25.64 B P/E(ttm) 20.70
Enterprise Value 23.92 B P/B 3.00
SYK- NYSE (USA)
Stryker Corporation
  • Currently 3.5/5
Business Predictability Rank: 3.5-Star (On Watch)
Back Testing Results:
Average gain of all 3.5-Star stocks: 9.3% per year.
% of Stocks that are in still loss if held for 10yrs: 9%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$67.67
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 2.454
SYK's Cash to Debt is ranked higher than
64% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. SYK: 2.454 )
SYK' s 10-Year Cash to Debt Range
Min: 0.05   Max: 164.16
Current: 2.45
0.05
164.16
Equity to Asset 0.651
SYK's Equity to Asset is ranked higher than
68% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. SYK: 0.651 )
SYK' s 10-Year Equity to Asset Range
Min: 0.26   Max: 0.73
Current: 0.65
0.26
0.73
F-Score: 5
Z-Score: 5
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 20.10
SYK's Operating margin (%) is ranked higher than
90% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. SYK: 20.10 )
SYK' s 10-Year Operating margin (%) Range
Min: -5.6   Max: 23.9
Current: 20.1
-5.6
23.9
Net-margin (%) 15
SYK's Net-margin (%) is ranked higher than
90% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. SYK: 15 )
SYK' s 10-Year Net-margin (%) Range
Min: 0.9   Max: 17.4
Current: 15
0.9
17.4
ROE (%) 15.1
SYK's ROE (%) is ranked higher than
90% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. SYK: 15.1 )
SYK' s 10-Year ROE (%) Range
Min: 2.9   Max: 25.9
Current: 15.1
2.9
25.9
ROA (%) 9.8
SYK's ROA (%) is ranked higher than
89% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. SYK: 9.8 )
SYK' s 10-Year ROA (%) Range
Min: 0.8   Max: 15.1
Current: 9.8
0.8
15.1
ROC (Joel Greenblatt) (%) 59.30
SYK's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. SYK: 59.30 )
SYK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13.8   Max: 70.9
Current: 59.3
-13.8
70.9
Revenue Growth (%) 7.6
SYK's Revenue Growth (%) is ranked higher than
87% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SYK: 7.6 )
SYK' s 10-Year Revenue Growth (%) Range
Min: 6.2   Max: 12.9
Current: 7.6
6.2
12.9
EBITDA Growth (%) 1.5
SYK's EBITDA Growth (%) is ranked higher than
83% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SYK: 1.5 )
SYK' s 10-Year EBITDA Growth (%) Range
Min: 1.5   Max: 101.1
Current: 1.5
1.5
101.1
EPS Growth (%) 5.2
SYK's EPS Growth (%) is ranked higher than
89% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SYK: 5.2 )
SYK' s 10-Year EPS Growth (%) Range
Min: 5.2   Max: 103.1
Current: 5.2
5.2
103.1
» SYK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

SYK Guru Trades in Q2 2012

Chuck Royce 45,485 sh (+56.14%)
PRIMECAP Management 304,500 sh (+24.11%)
Ken Fisher 8,656 sh (+0.65%)
Donald Yacktman 5,588,299 sh (+0.37%)
John Hussman 500,000 sh (unchged)
Robert Olstein 145,000 sh (unchged)
Murray Stahl 5,500 sh (unchged)
Paul Tudor Jones 43,400 sh (-3.98%)
Pioneer Investments 960,734 sh (-7.58%)
Jeremy Grantham 518,792 sh (-8.34%)
Mario Gabelli 9,275 sh (-48.1%)
Joel Greenblatt 9,114 sh (-59.17%)
Ray Dalio 7,819 sh (-84.49%)
Jim Simons 55,200 sh (-86.29%)
Steven Cohen 61,973 sh (-89.52%)
» More
Q3 2012

SYK Guru Trades in Q3 2012

Joel Greenblatt 76,455 sh (+738.87%)
Ray Dalio 54,706 sh (+599.65%)
Donald Yacktman 9,720,600 sh (+73.95%)
Chuck Royce 55,625 sh (+22.29%)
Murray Stahl 5,639 sh (+2.53%)
Robert Olstein 145,000 sh (unchged)
Yacktman Focused Fund 4,457,523 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Yacktman Fund 3,900,000 sh (unchged)
Pioneer Investments Sold Out
Jim Simons Sold Out
John Hussman Sold Out
Mario Gabelli Sold Out
Ken Fisher 8,586 sh (-0.81%)
Jeremy Grantham 505,092 sh (-2.64%)
Steven Cohen 20,476 sh (-66.96%)
Paul Tudor Jones 10,400 sh (-76.04%)
» More
Q4 2012

SYK Guru Trades in Q4 2012

Jim Simons 302,300 sh (New)
George Soros 75,000 sh (New)
Ray Dalio 78,006 sh (+42.59%)
Chuck Royce 72,890 sh (+31.04%)
Yacktman Fund 4,900,000 sh (+25.64%)
Donald Yacktman 12,064,853 sh (+24.12%)
Yacktman Focused Fund 5,100,000 sh (+14.41%)
Jeremy Grantham 448,264 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Murray Stahl Sold Out
Ken Fisher 8,395 sh (-2.22%)
Steven Cohen 19,904 sh (-2.79%)
Robert Olstein 139,000 sh (-4.14%)
Joel Greenblatt 64,239 sh (-15.98%)
Paul Tudor Jones 6,300 sh (-39.42%)
» More
Q1 2013

SYK Guru Trades in Q1 2013

Vanguard Health Care Fund 1,433,500 sh (New)
Jeremy Grantham 922,064 sh (+105.7%)
Joel Greenblatt 73,682 sh (+14.7%)
Chuck Royce 82,600 sh (+13.32%)
Paul Tudor Jones 6,800 sh (+7.94%)
Donald Yacktman 12,069,183 sh (+0.04%)
PRIMECAP Management 304,500 sh (unchged)
Yacktman Focused Fund 5,100,000 sh (unchged)
Yacktman Fund 4,900,000 sh (unchged)
George Soros Sold Out
Steven Cohen Sold Out
Ken Fisher 8,000 sh (-4.71%)
Robert Olstein 108,000 sh (-22.3%)
Ray Dalio 6,552 sh (-91.6%)
Jim Simons 7,300 sh (-97.59%)
» More
» Details

Insider Trades

Latest Guru Trades with SYK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-03-31 New Buy0.37%$54.82 - $66.81 $ 67.678%1433500
George Soros 2013-03-31 Sold Out 0.05%$54.82 - $66.81 $ 67.678%0
Ray Dalio 2013-03-31 Reduce -91.6%0.04%$54.82 - $66.81 $ 67.678%6552
Donald Yacktman 2012-12-31 Add 24.12%0.78%$52 - $56.57 $ 67.6726%12064853
Yacktman Fund 2012-12-31 Add 25.64%0.76%$52 - $56.57 $ 67.6726%4900000
Yacktman Focused Fund 2012-12-31 Add 14.41%0.55%$52 - $56.57 $ 67.6726%5100000
George Soros 2012-12-31 New Buy0.05%$52 - $56.57 $ 67.6726%75000
Ray Dalio 2012-12-31 Add 42.59%0.01%$52 - $56.57 $ 67.6726%78006
Donald Yacktman 2012-09-30 Add 73.95%1.4%$50.74 - $56.21 $ 67.6726%9720600
John Hussman 2012-09-30 Sold Out 0.52%$50.74 - $56.21 $ 67.6726%0
Joel Greenblatt 2012-09-30 Add 738.87%0.25%$50.74 - $56.21 $ 67.6726%76455
Ray Dalio 2012-09-30 Add 599.65%0.04%$50.74 - $56.21 $ 67.6726%54706
Mario Gabelli 2012-09-30 Sold Out 0.0038%$50.74 - $56.21 $ 67.6726%0
Joel Greenblatt 2012-06-30 Reduce -59.17%0.07%$49.7 - $55.99 $ 67.6727%9114
Ray Dalio 2012-06-30 Reduce -84.49%0.04%$49.7 - $55.99 $ 67.6727%7819
PRIMECAP Management 2012-06-30 Add 24.11%0.01%$49.7 - $55.99 $ 67.6727%304500
Mario Gabelli 2012-06-30 Reduce -48.1%$49.7 - $55.99 $ 67.6727%9275
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Top Ranked Articles about Stryker Corporation

Yacktman Fund Buys Dell Inc, Stryker Corporation, Coca-cola Co, Sells H&R Block Inc, Research In Motion Ltd, Liberty Ventures
January 29, 2013
Yacktman Fund - Yacktman Fund Buys Dell Inc, Stryker Corporation, Coca-cola Co, Sells H&R Block Inc, Research In Motion Ltd, Liberty Ventures
Besides the 13F of Yacktman Asset Management and Yacktman Focused Fund, we also started to track the portfolio of Yacktman Fund. Yacktman Fund is the flagship fund of Don Yacktman. The fund has achieved 10.6% of annual return over the past 10 years. It heavily invests in high quality large caps. As of Dec. 31, the fund has 51% of asset in top 10 positions and 16% in cash. Read more...
Donald Yacktman Finds Two Undervalued Companies in His Most Bought, In-Favor Sector of Q3
December 4, 2012
Donald Yacktman - Donald Yacktman Finds Two Undervalued Companies In His Most Bought, In-Favor Sector Of Q3
Donald Yacktman is an expert at identifying out-of-favor or undervalued sectors, buying them at the right price and ultimately profiting from their resurgence. “We use a variety of techniques to find ideas, including screens, although the best opportunities are often created because of short-term challenges within a business or its sector,” he said recently. Read more...
Weekly Top Insider Sells: GOOG, SYK, TDG, CIE, EW
July 2, 2012
According to GuruFocus Insider Data, these are the largest insider sells during the past week. The overall trend of insiders is illustrated in the chart below: Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 20.70
SYK's P/E(ttm) is ranked higher than
69% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 22.90 vs. SYK: 20.70 )
SYK' s 10-Year P/E(ttm) Range
Min: 11.3   Max: 80.46
Current: 20.7
11.3
80.46
P/B 3.00
SYK's P/B is ranked higher than
53% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. SYK: 3.00 )
SYK' s 10-Year P/B Range
Min: 2.21   Max: 13.5
Current: 3
2.21
13.5
P/S 2.98
SYK's P/S is ranked higher than
54% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. SYK: 2.98 )
SYK' s 10-Year P/S Range
Min: 1.93   Max: 5.76
Current: 2.98
1.93
5.76
PFCF 15.60
SYK's PFCF is ranked higher than
77% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 21.03 vs. SYK: 15.60 )
SYK' s 10-Year PFCF Range
Min: 11.63   Max: 62.01
Current: 15.6
11.63
62.01
EV-to-EBIT 14.7
SYK's EV-to-EBIT is ranked higher than
75% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 18.50 vs. SYK: 14.7 )
SYK' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 181.4
Current: 14.7
6.8
181.4
PEG 5.3
SYK's PEG is ranked higher than
50% of the 84 Companies
in the Global Medical Devices industry.

( Industry Median: 2.22 vs. SYK: 5.3 )
SYK' s 10-Year PEG Range
Min: 0.58   Max: 5.3
Current: 5.3
0.58
5.3
Shiller P/E 21.1
SYK's Shiller P/E is ranked lower than
100% of the Companies
in the Global Medical Devices industry.

( Industry Median: vs. SYK: 21.1 )
SYK' s 10-Year Shiller P/E Range
Min: 15.77   Max: 79.73
Current: 21.1
15.77
79.73

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 1.41
SYK's Dividend Yield is ranked higher than
81% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SYK: 1.41 )
SYK' s 10-Year Dividend Yield Range
Min: 0.13   Max: 1.66
Current: 1.41
0.13
1.66
Dividend Payout 0.292
SYK's Dividend Payout is ranked higher than
62% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. SYK: 0.292 )
SYK' s 10-Year Dividend Payout Range
Min: 0.05   Max: 0.66
Current: 0.29
0.05
0.66
Dividend growth (3y) 56.6
SYK's Dividend growth (3y) is ranked higher than
100% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SYK: 56.6 )
SYK' s 10-Year Dividend growth (3y) Range
Min: -9.1   Max: 56.6
Current: 56.6
-9.1
56.6
Yield on cost (5-Year) 7.08
SYK's Yield on cost (5-Year) is ranked higher than
99% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SYK: 7.08 )
SYK' s 10-Year Yield on cost (5-Year) Range
Min: 0.66   Max: 8.4
Current: 7.08
0.66
8.4
Share Buyback Rate 1
SYK's Share Buyback Rate is ranked higher than
94% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SYK: 1 )
SYK' s 10-Year Share Buyback Rate Range
Min: 1.5   Max: -1.2
Current: 1

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 15.1
SYK's Price/Net Current Asset Value is ranked higher than
63% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. SYK: 15.1 )
SYK' s 10-Year Price/Net Current Asset Value Range
Min: 11.4   Max: 28.5
Current: 15.1
11.4
28.5
Price/Tangible Book 5.1
SYK's Price/Tangible Book is ranked higher than
50% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. SYK: 5.1 )
SYK' s 10-Year Price/Tangible Book Range
Min: 3.7   Max: 632.4
Current: 5.1
3.7
632.4
Price/DCF (Projected) 1.3
SYK's Price/DCF (Projected) is ranked higher than
83% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. SYK: 1.3 )
SYK' s 10-Year Price/DCF (Projected) Range
Min: 0.9   Max: 9.3
Current: 1.3
0.9
9.3
Price/Median PS Value 0.7
SYK's Price/Median PS Value is ranked higher than
80% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. SYK: 0.7 )
SYK' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 1.3
Current: 0.7
0.6
1.3
Price/Graham Number 2.1
SYK's Price/Graham Number is ranked higher than
57% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. SYK: 2.1 )
SYK' s 10-Year Price/Graham Number Range
Min: 1.5   Max: 36.7
Current: 2.1
1.5
36.7
Earnings Yield (Greenblatt) 6.80
SYK's Earnings Yield (Greenblatt) is ranked higher than
84% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. SYK: 6.80 )
SYK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 14.6
Current: 6.8
0.6
14.6
Forward Rate of Return (Yacktman) 7.62
SYK's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SYK: 7.62 )
SYK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.8   Max: 43.8
Current: 7.62
-0.8
43.8

Business Description

Stryker Corporation was incorporated in Michigan in 1946 as the successor company to a business founded in 1941. It is a medical technology company. The Company's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties. The Company's three reportable business segments are Reconstructive, MedSurg, and Neurotechnology and Spine. The Reconstructive segment includes orthopaedic reconstructive (hip and knee) and trauma implant systems as well as other related products. The MedSurg segment include surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); reprocessed and remanufactured medical devices; as well as other medical device products used in a variety of medical specialties.. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company's neurotechnology offering includes products used for minimally invasive endovascular techniques, as well as a comprehensive line of products for traditional brain and open skull base surgical procedures, orthobiologic and biosurgery products including synthetic bone grafts and vertebral augmentation products, as well as minimally invasive products for the treatment of acute ischemic stroke. The Company also develops, manufactures and markets spinal implant products including cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. In the United States, most of the Company's products are marketed directly to doctors, hospitals and other health-care facilities. The Company's main competitors in neurotechnology are Covidien and Micrus Endovascular, LLC and in spine products are Medtronic Sofamor Danek, Inc., DePuy Spine, Inc. and Synthes, Inc. The Company's businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SMA, ZMH, STJ, EW
Traded in other countries:SYK.Germany
» More Articles for SYK

Headlines

Articles On GuruFocus.com
Forecasting Future Earnings Is the Key to Successful Stock Investing, Consensus Analysts’ Estimate Mar 14 2013 
Solid but expensive Feb 23 2013 
comment on SYK Feb 04 2013 
Donald Yacktman Buys Dell Inc, Stryker, Coca-Cola, IBM, Sells Research in Motion, H&R Block Feb 02 2013 
Yacktman Fund Buys Dell Inc, Stryker Corporation, Coca-cola Co, Sells H&R Block Inc, Research In Mot Jan 29 2013 
Stryker Corporation (SYK) Dividend Stock Analysis Jan 11 2013 
Seven Dividend Hikers in the News Dec 10 2012 
Donald Yacktman Finds Two Undervalued Companies in His Most Bought, In-Favor Sector of Q3 Dec 04 2012 
My Best Healthcare Stock Picks For 2013 | Last Year’s Picks Gained 31.55% Dec 04 2012 
8 Stocks with Strong Dividend Growth Metrics Oct 31 2012 

More From Our Partners
Positive Data for COV's Solitaire - Analyst Blog Jun 17 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK